Search

Your search keyword '"Deepu, A"' showing total 526 results

Search Constraints

Start Over You searched for: Author "Deepu, A" Remove constraint Author: "Deepu, A" Publisher elsevier bv Remove constraint Publisher: elsevier bv
526 results on '"Deepu, A"'

Search Results

1. Ultrasound-driven facile fabrication of Pd doped SnO2 hierarchical superstructures: Structural, growth mechanism, dermatoglyphics, and anti-cancer activity

2. Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

3. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

5. Straightforward green synthesis of Fe3+ doped ZnAl2O4 spinel structure and potential applications in alleviating thrombosis, oxidative stress, data encryption and dermatoglyphics

7. The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

11. Facile fabrication of arecanut palm sheath based robust hydrophobic cellulose nanopapers via self-assembly of ZnO nanoflakes and its shelf-life prediction for sustainable packaging applications

12. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study

17. An evaluation of ECG data fusion algorithms for wearable IoT sensors

18. Designing energy transfer-based color-tunable, information-encrypting, luminous hydro-gels, and latent fingerprint detection systems using BaLa2ZnO5:Tb3+, Bi3+ nanophosphors

22. MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

23. POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

24. MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

26. POSTER: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

27. P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

28. Oral Abstract: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

29. A comparison of internal fixation and hemiarthroplasty in the management of un- or minimally displaced hip fractures in patients over 60 years old

30. Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma

31. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

39. Coverage, Delays and Implementation Challenges Of ‘Direct Benefit Transfer’ in the National Tuberculosis Elimination Programme – A Mixed Methods Study

45. Phenytoin-induced organising pneumonia: An unknown entity

46. Symptomatology of Sigatoka leaf spot disease in banana landraces and identification of its pathogen as Mycosphaerella eumusae

48. An Exploratory Analysis on the Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Received BCMA CAR-T Therapy in the Cartitude-1 Study

Catalog

Books, media, physical & digital resources